(Q46319910)

21 December 2017

title

Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics (English)

1 reference

21 December 2017

1 reference

Qian Xiang

1

1 reference

21 December 2017

Yimin Cui

series ordinal

2

1 reference

21 December 2017

Xia Zhao

series ordinal

3

1 reference

21 December 2017

Nan Zhao

series ordinal

4

1 reference

21 December 2017

publication date

1 July 2013

1 reference

21 December 2017

published in

Pharmacogenomics

1 reference

21 December 2017

volume

14

1 reference

21 December 2017

issue

10

1 reference

21 December 2017

page(s)

1179-1189

1 reference

21 December 2017

Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Bedside evaluation of thienopyridine antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.108

21 January 2018

Identifiers

DOI

10.2217/PGS.13.108

1 reference

21 December 2017

1 reference

21 December 2017